Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit Finally Here But Uncertainty Not Over For Biopharma

Doubts Persist On Regulatory Alignment And Migration

Executive Summary

A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.

You may also be interested in...



Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits

Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.

Podcast: Key Takeaways From J.P. Morgan

Scrip journalists join Datamonitor Healthcare's Mike Ramirez to share their impressions from the 2020 J.P. Morgan conference in San Francisco. Talking points range from M&A to the drug pricing debate, via individual company strategies, the impending US election and more.

 

US Approval For Peanut Allergy Therapy Palforzia

Aimmune has secured approval for the first ever peanut allergy treatment, but safety, cost and administration issues could limit the drug's uptake.

Topics

UsernamePublicRestriction

Register

SC141574

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel